<p>Oramed Pharmaceuticals Inc. (NASDAQ:ORMP - 获取免费报告) 的股价在周一的交易中突破了其 50 日移动平均线。该股票的 50 日移动平均价为 3.26 美元，最高交易价为 3.35 美元。Oramed Pharmaceuticals 的股票最后交易价为 3.31 美元，成交量为 368,355 股。</p>
<p>获取 <strong>Oramed Pharmaceuticals</strong> 的提醒：</p>
<h2>华尔街分析师观点</h2>
<p>一些股票分析师最近对 ORMP 股票进行了评估。Weiss Ratings 在 12 月 29 日的报告中重申了对 Oramed Pharmaceuticals 股票的 “持有（c）” 评级。Wall Street Zen 在 11 月 1 日的研究报告中将 Oramed Pharmaceuticals 的股票评级提升至 “持有”。根据 MarketBeat.com 的数据，一位股票研究分析师对该股票给予了持有评级，目前该公司的共识评级为 “持有”。</p>
<p><strong>阅读我们对 ORMP 的最新股票分析</strong></p>
<h2>Oramed Pharmaceuticals 价格表现</h2>
<p>该公司的 50 日移动平均价格为 3.26 美元，200 日移动平均价格为 2.71 美元。该公司的市值为 1.3174 亿美元，市盈率为 2.63，贝塔值为 1.34。</p>
<h2>Oramed Pharmaceuticals 宣布分红</h2>
<p>该公司最近还披露了一项分红，该分红于 1 月 26 日（周一）支付。1 月 16 日（周五）的股东获得每股 0.25 美元的分红。该分红的除息日期为 1 月 16 日（周五）。Oramed Pharmaceuticals 的分红支付比率目前为 19.84%。</p>
<h2>机构资金流入和流出</h2>
<p>几家机构投资者和对冲基金最近买卖了该股票的股份。美国银行在第三季度将其在 Oramed Pharmaceuticals 的持股增加了 4.4%。美国银行目前拥有 149,667 股该生物技术公司的股票，价值 395,000 美元，此前在上个季度购买了 6,261 股。XTX Topco Ltd 在第四季度将其在 Oramed Pharmaceuticals 的股份增加了 59.9%。XTX Topco Ltd 目前拥有 38,182 股该生物技术公司的股票，价值 109,000 美元，此前在此期间购买了 14,297 股。Jane Street Group LLC 在第一季度将其在 Oramed Pharmaceuticals 的持股增加了 35.3%。Jane Street Group LLC 目前拥有 67,173 股该生物技术公司的股票，价值 144,000 美元，此前在上个季度增加了 17,510 股。Squarepoint Ops LLC 在第四季度将其在 Oramed Pharmaceuticals 的股份增加了 95.1%。Squarepoint Ops LLC 目前拥有 58,272 股该生物技术公司的股票，价值 166,000 美元，此前在上个季度增加了 28,406 股。最后，Quadrature Capital Ltd 在第四季度获得了 Oramed Pharmaceuticals 的新头寸，价值约 119,000 美元。12.73% 的股票由机构投资者和对冲基金持有。</p>
<h2>Oramed Pharmaceuticals 公司简介</h2>
<p>（获取免费报告）</p>
<p>Oramed Pharmaceuticals Inc 是一家临床阶段的生物技术公司，专注于开发专有的口服药物递送系统，初步重点是糖尿病管理。公司总部位于以色列耶路撒冷，利用其专利的蛋白质包封技术 “口服递送平台”，将注射疗法转变为患者友好的口服制剂。Oramed 的平台旨在保护敏感的蛋白质和肽免受胃肠道降解，从而实现成功的吸收和系统递送。</p>
<p>该公司的主要候选药物 ORMD-0801 是一种用于 2 型糖尿病患者的口服胰岛素胶囊，目前正在进行第三阶段临床试验。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票比 Oramed Pharmaceuticals 更好</li>
<li>埃隆·马斯克已经让我成为 “富有的人”</li>
<li>埃隆的秘密人工智能合作伙伴？</li>
<li>银价 500 美元？“赤字数学” 认为这是可能的。</li>
<li>埃隆·马斯克：这可能将 100 美元变成 100,000 美元</li>
<li>巴菲特、盖茨和贝索斯悄悄抛售股票——原因在这里</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Oramed Pharmaceuticals 吗？</h2>
<p>在你考虑 Oramed Pharmaceuticals 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已经识别出五只股票，顶级分析师正在悄悄地向客户推荐，现在购买，以便在更广泛的市场注意到之前……而 Oramed Pharmaceuticals 并不在名单上。</p>
<p>虽然 Oramed Pharmaceuticals 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

Oramed制药

<p>Oramed 制药（NASDAQ:ORMP）股票价格超过其 50 日移动平均线 3.26 美元，最高达到 3.35 美元，最终收于 3.31 美元。该公司的市值为 1.3174 亿美元，市盈率为 2.63。分析师对该股票维持 “持有” 的共识评级。最近，Oramed 宣布每股派息 0.25 美元，派息率为 19.84%。机构投资者持有该股票的 12.73%，多个公司在其持仓上有显著增加</p>

<p>Oramed Pharmaceuticals Inc. (NASDAQ:ORMP - Get Free Report)'s stock price passed above its 50-day moving average during trading on Monday . The stock has a 50-day moving average of $3.26 and traded as high as $3.35. Oramed Pharmaceuticals shares last traded at $3.31, with a volume of 368,355 shares trading hands.</p>
<div class="lb-trans"><p>Oramed Pharmaceuticals Inc. (NASDAQ:ORMP - 获取免费报告) 的股价在周一的交易中突破了其 50 日移动平均线。该股票的 50 日移动平均价为 3.26 美元，最高交易价为 3.35 美元。Oramed Pharmaceuticals 的股票最后交易价为 3.31 美元，成交量为 368,355 股。</p>
</div><p>Get <strong>Oramed Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Oramed Pharmaceuticals</strong> 的提醒：</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><p>A number of equities analysts have recently weighed in on ORMP shares. Weiss Ratings reiterated a &#34;hold (c)&#34; rating on shares of Oramed Pharmaceuticals in a report on Monday, December 29th. Wall Street Zen raised shares of Oramed Pharmaceuticals to a &#34;hold&#34; rating in a research note on Saturday, November 1st. One equities research analyst has rated the stock with a Hold rating, According to MarketBeat.com, the company presently has a consensus rating of &#34;Hold&#34;.</p>
<div class="lb-trans"><p>一些股票分析师最近对 ORMP 股票进行了评估。Weiss Ratings 在 12 月 29 日的报告中重申了对 Oramed Pharmaceuticals 股票的 “持有（c）” 评级。Wall Street Zen 在 11 月 1 日的研究报告中将 Oramed Pharmaceuticals 的股票评级提升至 “持有”。根据 MarketBeat.com 的数据，一位股票研究分析师对该股票给予了持有评级，目前该公司的共识评级为 “持有”。</p>
</div><p><strong>Read Our Latest Stock Analysis on ORMP</strong></p>
<div class="lb-trans"><p><strong>阅读我们对 ORMP 的最新股票分析</strong></p>
</div><h2>Oramed Pharmaceuticals Price Performance</h2>
<div class="lb-trans"><h2>Oramed Pharmaceuticals 价格表现</h2>
</div><p>The company's 50 day moving average price is $3.26 and its 200 day moving average price is $2.71. The firm has a market cap of $131.74 million, a PE ratio of 2.63 and a beta of 1.34.</p>
<div class="lb-trans"><p>该公司的 50 日移动平均价格为 3.26 美元，200 日移动平均价格为 2.71 美元。该公司的市值为 1.3174 亿美元，市盈率为 2.63，贝塔值为 1.34。</p>
</div><h2>Oramed Pharmaceuticals Announces Dividend</h2>
<div class="lb-trans"><h2>Oramed Pharmaceuticals 宣布分红</h2>
</div><p>The business also recently disclosed a dividend, which was paid on Monday, January 26th. Stockholders of record on Friday, January 16th were given a dividend of $0.25 per share. The ex-dividend date of this dividend was Friday, January 16th. Oramed Pharmaceuticals's dividend payout ratio is currently 19.84%.</p>
<div class="lb-trans"><p>该公司最近还披露了一项分红，该分红于 1 月 26 日（周一）支付。1 月 16 日（周五）的股东获得每股 0.25 美元的分红。该分红的除息日期为 1 月 16 日（周五）。Oramed Pharmaceuticals 的分红支付比率目前为 19.84%。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>Several institutional investors and hedge funds have recently bought and sold shares of the stock. Bank of America Corp DE raised its position in Oramed Pharmaceuticals by 4.4% in the 3rd quarter. Bank of America Corp DE now owns 149,667 shares of the biotechnology company's stock valued at $395,000 after purchasing an additional 6,261 shares in the last quarter. XTX Topco Ltd increased its stake in shares of Oramed Pharmaceuticals by 59.9% during the fourth quarter. XTX Topco Ltd now owns 38,182 shares of the biotechnology company's stock worth $109,000 after buying an additional 14,297 shares during the period. Jane Street Group LLC raised its holdings in Oramed Pharmaceuticals by 35.3% in the first quarter. Jane Street Group LLC now owns 67,173 shares of the biotechnology company's stock valued at $144,000 after acquiring an additional 17,510 shares in the last quarter. Squarepoint Ops LLC lifted its stake in Oramed Pharmaceuticals by 95.1% in the fourth quarter. Squarepoint Ops LLC now owns 58,272 shares of the biotechnology company's stock worth $166,000 after acquiring an additional 28,406 shares during the last quarter. Finally, Quadrature Capital Ltd acquired a new position in Oramed Pharmaceuticals during the 4th quarter worth approximately $119,000. 12.73% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>几家机构投资者和对冲基金最近买卖了该股票的股份。美国银行在第三季度将其在 Oramed Pharmaceuticals 的持股增加了 4.4%。美国银行目前拥有 149,667 股该生物技术公司的股票，价值 395,000 美元，此前在上个季度购买了 6,261 股。XTX Topco Ltd 在第四季度将其在 Oramed Pharmaceuticals 的股份增加了 59.9%。XTX Topco Ltd 目前拥有 38,182 股该生物技术公司的股票，价值 109,000 美元，此前在此期间购买了 14,297 股。Jane Street Group LLC 在第一季度将其在 Oramed Pharmaceuticals 的持股增加了 35.3%。Jane Street Group LLC 目前拥有 67,173 股该生物技术公司的股票，价值 144,000 美元，此前在上个季度增加了 17,510 股。Squarepoint Ops LLC 在第四季度将其在 Oramed Pharmaceuticals 的股份增加了 95.1%。Squarepoint Ops LLC 目前拥有 58,272 股该生物技术公司的股票，价值 166,000 美元，此前在上个季度增加了 28,406 股。最后，Quadrature Capital Ltd 在第四季度获得了 Oramed Pharmaceuticals 的新头寸，价值约 119,000 美元。12.73% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Oramed Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>Oramed Pharmaceuticals 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Oramed Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of proprietary oral drug delivery systems, with an initial emphasis on diabetes management. Headquartered in Jerusalem, Israel, the company leverages its patented protein encapsulation technology, the “Oral Delivery Platform,” to transform injectable therapies into patient-friendly oral formulations. Oramed's platform is designed to protect sensitive proteins and peptides from degradation in the gastrointestinal tract, enabling successful absorption and systemic delivery.</p>
<div class="lb-trans"><p>Oramed Pharmaceuticals Inc 是一家临床阶段的生物技术公司，专注于开发专有的口服药物递送系统，初步重点是糖尿病管理。公司总部位于以色列耶路撒冷，利用其专利的蛋白质包封技术 “口服递送平台”，将注射疗法转变为患者友好的口服制剂。Oramed 的平台旨在保护敏感的蛋白质和肽免受胃肠道降解，从而实现成功的吸收和系统递送。</p>
</div><p>The company's lead candidate, ORMD-0801, is an oral insulin capsule for patients with type 2 diabetes, currently advancing through Phase 3 clinical trials.</p>
<div class="lb-trans"><p>该公司的主要候选药物 ORMD-0801 是一种用于 2 型糖尿病患者的口服胰岛素胶囊，目前正在进行第三阶段临床试验。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Oramed Pharmaceuticals</li>
<li>Elon Musk already made me a “wealthy man”</li>
<li>Elon’s Secret AI Partner?</li>
<li>Silver $500? The &#34;Deficit Math&#34; says it's possible.</li>
<li>Elon Musk: This Could Turn $100 into $100,000</li>
<li>Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Oramed Pharmaceuticals 更好</li>
<li>埃隆·马斯克已经让我成为 “富有的人”</li>
<li>埃隆的秘密人工智能合作伙伴？</li>
<li>银价 500 美元？“赤字数学” 认为这是可能的。</li>
<li>埃隆·马斯克：这可能将 100 美元变成 100,000 美元</li>
<li>巴菲特、盖茨和贝索斯悄悄抛售股票——原因在这里</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Oramed Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Oramed Pharmaceuticals 吗？</h2>
</div><p>Before you consider Oramed Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Oramed Pharmaceuticals 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oramed Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已经识别出五只股票，顶级分析师正在悄悄地向客户推荐，现在购买，以便在更广泛的市场注意到之前……而 Oramed Pharmaceuticals 并不在名单上。</p>
</div><p>While Oramed Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Oramed Pharmaceuticals 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Oramed 制药（NASDAQ:ORMP）的股价突破了 50 日移动平均线 - 以下是原因